ライフサイエンスコーパス: meningococcal vaccine

1 support for inclusion of this molecule in a meningococcal vaccine.

2 ingitidis serogroups included in the current meningococcal vaccine.

3 nactivated influenza vaccine or quadrivalent meningococcal vaccine.

4 lopment not only for gonorrhoea but also for meningococcal vaccines.

5 rvations support the incorporation of Opa in meningococcal vaccines.

6 ructure that may affect the effectiveness of meningococcal vaccines.

7 al, Haemophilus influenzae type b (Hib), and meningococcal vaccines.

8 ome outer membrane protein-based serogroup B meningococcal vaccines.

9 -vaccine era, use of a polyvalent conjugated meningococcal vaccine, and influenza vaccination during

10 s to factor H (fH)-binding protein (fHBP), a meningococcal vaccine antigen, activate classical comple

11 The meningococcal vaccine antigen, factor H (FH)-binding pro

12 tibody production in mice and is a candidate meningococcal vaccine antigen.

13 eful characteristic for an effective group B meningococcal vaccine antigen.

14 Other group B meningococcal vaccines are in development.

15 New meningococcal vaccines are undergoing clinical trials, a

16 Patients received meningococcal vaccine at a screening visit and 2 weeks l

17 The meningococcal vaccine candidate factor H binding protein

18 The meningococcal vaccine candidate factor H-binding protein

19 Genome-derived neisserial Ag (GNA) 1870 is a meningococcal vaccine candidate that can be subdivided i

20 Factor H-binding protein (fHbp) is a novel meningococcal vaccine candidate that elicits serum antib

21 embrane protein previously investigated as a meningococcal vaccine candidate.

22 rrently under evaluation as a broad-spectrum meningococcal vaccine candidate.

23 proteins that have been considered potential meningococcal vaccine candidates.

24 te that molecular mimetics have potential as meningococcal vaccine candidates.

25 The older meningococcal vaccine, composed of capsular polysacchari

26 tetravalent (serogroups A, C, Y, and W-135) meningococcal vaccine conjugated to diphtheria toxoid at

27 Meningococcal vaccines containing factor H binding prote

28 ived 3 doses of outer-membrane protein (OMP) meningococcal vaccine developed in either Cuba or Norway

29 creased in recent years, but the efficacy of meningococcal vaccine during mass vaccination campaigns

30 and cerebrospinal fluid (CSF) samples from a meningococcal vaccine field trial performed in Iquique,

31 Use of the quadrivalent meningococcal vaccine for control of outbreaks has incre

32 a demonstrate the feasibility of preparing a meningococcal vaccine from a single recombinant protein

33 cine group than in those in the quadrivalent meningococcal vaccine group (n=60 vs n=37; p=0.02).

34 eported in 60 (3%) women in the quadrivalent meningococcal vaccine group and 61 (3%) women in the tri

35 ere first episodes (n=77 in the quadrivalent meningococcal vaccine group vs n=52 in the trivalent ina

36 93 (88%) of 2041 infants in the quadrivalent meningococcal vaccine group were followed up until age 6

37 round the world, and a hexavalent PorA-based meningococcal vaccine has recently been developed in The

38 A significant problem in efficacy trials of meningococcal vaccines has been accurate identification

39 New conjugate meningococcal vaccines have successfully reduced endemic

40 e candidates in the search for comprehensive meningococcal vaccines; however, the formulation of OMP

41 p vaccine), meningococcal disease (conjugate meningococcal vaccine), human papillomavirus (for female

42 re potentially preventable with the licensed meningococcal vaccine in 82.8% of 15 through 24 year old

43 llenge will be effective introduction of new meningococcal vaccines into developing countries, especi

44 The presently licensed meningococcal vaccine is a tetravalent capsular polysacc

45 Herd protection by meningococcal vaccines is conferred by population-level

46 Assessment of new serogroup B meningococcal vaccines is hampered by a scarcity of data

47 opose that outer membrane vesicle-containing meningococcal vaccines may be more efficacious if purged

48 -OMVs as adjuvants or as portions of group B meningococcal vaccines may help improve survival and out

49 in SLSJ, using the 4-component protein-based meningococcal vaccine (MenB-4C).

50 ng protein (fHbp; a key component of group B meningococcal vaccines) molecule.

51 d influenza vaccine (n=2108) or quadrivalent meningococcal vaccine (n=2085).

52 ve either an influenza vaccine or a control (meningococcal vaccine, pneumococcal vaccine, or placebo)

53 families and cost-effectiveness analyses for meningococcal vaccine programs.

54 The group A meningococcal vaccine (PsA-TT) clinical development plan

55 During the first introduction of a group A meningococcal vaccine (PsA-TT) in 2010-2011 and its roll

56 The rollout of the group A meningococcal vaccine, PsA-TT, in Africa's meningitis be

57 hat for serogroups prevented by quadrivalent meningococcal vaccines, public health response to outbre

58 f tetanus/diphtheria/acellular pertussis and meningococcal vaccines, respectively, was delayed by 1 w

59 In 2005, a new meningococcal vaccine, tetravalent meningococcal conjuga

60 was more common in women given quadrivalent meningococcal vaccine than in those given trivalent inac

61 ongoing to develop a serogroup B vaccine and meningococcal vaccines that are immunogenic in infants a

62 Meningococcal vaccines that target both NspA and FHbp ar

63 A conjugate group A meningococcal vaccine to prevent epidemics of meningitis

64 d diagnostic of disease in future testing of meningococcal vaccines to improve efficacy analyses.

65 A 'tailor-made' group B meningococcal vaccine was successfully used to control a

66 Children and adult recipients of either meningococcal vaccine were more likely than controls to

67 vels elicited by two efficacious serogroup B meningococcal vaccines were measured in a controlled tri

68 i-TT), Vi-polysaccharide (Vi-PS), or control meningococcal vaccine with a computer-generated randomis

69 se data suggest that neither serogroup B OMP meningococcal vaccine would confer protection during a h